Transgene and BioInvent’s Armed Oncolytic Virus BT-001 Shows Positive Local, Abscopal, and Sustained Antitumoral Activity in Advanced Refractory Tumors BT-001 in combination with pembrolizumab is well tolerated and shows sustained antitumoral activity in both injected and non-injected lesions Data support further development of BT-001 in solid tumors to improve response to cancer immunotherapy Strasbourg, France, and Lund, Sweden, October 20, 2025, 08:30 a.m. CEST – Transgene (Euronext Paris: TNG), a biotech company that designs and develops virus-based immunotherapies for the treatment...
Le virus oncolytique armé BT-001, développé par Transgene et BioInvent, montre une activité antitumorale locale, à distance et durable chez des patients atteints de tumeurs avancées en échec thérapeutique BT-001, administré en combinaison avec pembrolizumab, est bien toléré et présente une activité antitumorale persistante dans des lésions injectées et non-injectées Les résultats obtenus soutiennent la poursuite du développement de BT-001 dans les tumeurs solides afin d'améliorer la réponse aux immunothérapies Strasbourg, France, et Lund, Suède, le 20 octobre 2025, 8 h 30 CEST – Transge...
Subsea 7 S.A. - 3Q25 earnings call notification Luxembourg – 13 October 2025 – Subsea 7 S.A. (Oslo Børs: SUBC, ADR: SUBCY) will publish its third quarter 2025 results for the period ended 30 September 2025 on Thursday 20 November 2025 at 08:00 CET. A conference call and simultaneous webcast for the investment community will be held on Thursday 20 November 2025 at 12:00 UK / 13:00 CET. From 08:00 CET the results announcement and the presentation to be reviewed during the conference call and webcast will be available on the Subsea7 website: Conference call registration: Phone: -c...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.